FirmAtlas
Company handbook · STE · Prepared by FirmAtlas · firmatlas.app · printed 2026-10-17
STE · CIK 1757898 · LATEST FILING: 10-Q JUN '26 · FILED AUG 7, 2026
STERIS plc
$222.66
−1.67 (−0.74%)
Close, Oct 16, 2026 · 52-week $195–269
Last fiscal year
STERIS plc reported revenue of $5.9B for the year ended Mar 31, 2026 (FY25), up 8.7% from FY24. Net income was $782M, operating cash flow $1.3B and free cash flow $972M. Source: 10-K filed May 29, 2026.
Market cap
$21.8B
P/E
27.1
EV/EBITDA
14.6x
P/B
3.0
Div yield
0.88%
ROIC
9.6%
Revenue 1Y
8.7%/yr
EPS 1Y
27.9%/yr
Shares 1Y
−0.5%
Loading chart…
Median
Daily closes, split-adjusted · ratios at each fiscal year end
Company
CEODaniel A. Carestio
HQDublin, Ireland
AuditorErnst & Young LLP
Employees18,000
Year endsMarch
Revenue by segment · FY25
Healthcare71%
Applied Sterilization Technologies19%
Life Science Member10%
Compounded growth & averages
10Y
5Y
3Y
TTM
Share price
12.3%
−0.2%
−0.2%
−7.3%
Upgrade to see 10 years
Share price: yearly compound rate of the traded close; the last column is the past year.
Where the cash went · FY24–FY25
$1.7B deployed
Capex
$739M
42.9%
Acquisitions
$74M
4.3%
Dividends
$462M
26.8%
Buybacks
$447M
25.9%
Operating cash flow over the period: $2.5B. Total debt changed by −$112M. R&D of $220M is already inside operating costs.
Growth engines
How much of the profit growth came from new investment, and how much from running the business better.
Upgrade to see 10 years
Financials
Last 2 years · Upgrade to see 10 years · USD millions · each year opens its 10-K · FY25 = year ended Mar 31, 2026 · change vs previous year
Last 4 quarters · USD millions · quarter-end month shown · change vs same quarter a year earlier
TTM = the last four quarters, to Jun '26. Balance-sheet rows show that latest quarter. “—” where the quarters do not add up to the annual figures. No TTM for cash: our quarterly rows do not hold short-term investments yet, and annual cash includes them.
Income
Revenue
5,460
5,936+8.7%
6,037
YoY
+8.7%
Gross profit
2,403
2,626+9.3%
2,683
Gross margin
44.0%
44.2%+0.2 pp
—
Operating income
867
1,102+27.1%
1,142
Operating margin
15.9%
18.6%+2.7 pp
—
EBITDA
1,343
1,588+18.3%
—
EBITDA margin
24.6%
26.8%+2.2 pp
—
Interest expense
86
61−29.7%
—
Interest coverage
15.56x
26.17x+10.61x
—
Net income
615
782+27.3%
805
YoY
+27.3%
Net margin
11.3%
13.2%+1.9 pp
—
EPS (diluted, $)
6.20
7.93+27.9%
—
YoY
+27.9%
Balance sheet
Total assets
10,147
10,737+5.8%
10,736
Cash & short-term investments
172
440+156.0%
—
Accounts receivable
1,044
1,093+4.7%
—
Inventory
581
632+8.7%
—
Net PP&E
1,956
2,161+10.5%
—
Other assets
6,393
6,412+0.3%
—
Total liabilities
3,543
3,554+0.3%
3,529
Accounts payable
281
339+20.7%
—
Total debt
2,044
1,932−5.5%
1,894
Other liabilities
1,219
1,283+5.3%
—
Shareholders’ equity
6,603
7,184+8.8%
7,207
Total liabilities = total assets − shareholders’ equity, so it includes minority interest where a company has one.
Cash flow statement · as filed
Cash from operations
1,148
1,341+16.8%
1,288
Net income
616
785+27.4%
—
Depreciation & amortization
476
486+2.2%
—
Stock-based compensation
57
62+7.5%
—
Working capital & other
(2)
8n/m
—
Cash from investing
389
(512)−231.8%
—
Capex
(370)
(369)n/m
—
PP&E sold
9
10+14.1%
—
Acquisitions
(54)
(20)n/m
—
Investments bought
(11)
(134)n/m
—
Other investing
815
0.1−100.0%
—
Cash from financing
(1,572)
(568)n/m
—
Dividends
(220)
(242)n/m
—
Buybacks
(211)
(236)n/m
—
Shares issued
26
33+29.0%
—
Other financing
(1,167)
(124)n/m
—
Net change in cash
(35)
268n/m
—
Free cash flow (OCF − capex)
778
972+25.0%
926
Where the cash went
Operating cash flow
1,148
1,341+16.8%
1,288
Reinvested in the business
424
389−8.3%
—
% of operating cash flow
36.9%
29.0%
Capex
370
369−0.3%
363
Acquisitions
54
20−62.8%
—
R&D (memo, already in costs)
108
113+4.9%
—
Free cash flow
778
972+25.0%
926
YoY
+25.0%
Returned to shareholders
431
477+10.7%
—
% of free cash flow
55.4%
49.1%
Dividends
220
242+10.0%
—
Buybacks
211
236+11.5%
—
Change in total debt
—
(112)
—
Cash left over
—
363
—
FCF conversion (FCF ÷ net income)
126.6%
124.3%−2.3 pp
—
Owner earnings
—
858
—
Owner earnings margin
—
14.5%
—
Buyback yield
0.9%
1.1%+0.1 pp
—
Returns & ratios
ROIC (all capital)
7.9%
9.6%+1.8 pp
—
ROIC (operating)
20.2%
24.1%+4.0 pp
—
Net debt / EBITDA
1.39x
0.94x−0.45x
—
Debt / equity
0.31x
0.27x−0.04x
—
Cash conversion cycle (days)
106
100−6 d
—
ROE
9.3%
10.9%+1.6 pp
—
ROA
6.1%
7.3%+1.2 pp
—
ROCE
9.5%
11.5%+2.0 pp
—
NOPAT
666
826+24.1%
—
Invested capital (operating)
3,301
3,547+7.5%
—
Invested capital (all)
8,475
8,676+2.4%
—
Reinvestment rate
—
29.8%
—
Debtor days
70
67−3 d
—
Inventory days
69
70+0 d
—
Days payable
34
37+4 d
—
Income
Sep '25
Dec '25
Mar '26
Jun '26
Revenue
1,460
1,496
1,588
1,493
vs year-ago quarter
Gross profit
646
656
697
684
Gross margin
44.2%
43.8%
43.9%
45.8%
Operating income
266
273
317
286
Net income
192
193
220
200
vs year-ago quarter
Net margin
13.1%
12.9%
13.9%
13.4%
EPS (diluted, $)
1.94
1.96
2.25
—
vs year-ago quarter
Balance sheet
Sep '25
Dec '25
Mar '26
Jun '26
Total assets
10,411
10,591
10,737
10,736
Cash & equivalents
319
424
440
482
Total debt
1,897
1,898
1,932
1,894
Shareholders’ equity
7,009
7,154
7,184
7,207
Cash flow
Sep '25
Dec '25
Mar '26
Jun '26
Operating cash flow
288
298
335
367
Capex
86
99
90
88
Free cash flow
201
200
245
280
vs year-ago quarter